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pDITORIAL COMMENT
omorbidity and
utcome in Patients
ith Coronary Artery Disease*
ark A. Hlatky, MD, FACC
tanford, California
ost patients have more than one health condition, and
herefore the assessment of comorbidity is important for
atient care, for quality assurance, and for the evaluation of
herapy. Comorbid diseases may affect multiple clinical
utcomes, including mortality, functional capacity, quality
f life, and cost. Clinical intuition tells us that diabetes, for
xample, has a strong effect on all of these outcomes and
hus that the presence or absence of diabetes should be
onsidered in the management of patients with coronary
isease. Other comorbid conditions, such as chronic lung
isease or renal insufficiency, probably have detrimental
ffects on outcome. Comorbid conditions in a patient with
oronary disease may affect outcome directly or indirectly by
educing the patient’s physiologic reserve and thereby in-
reasing the risk of adverse outcome of coronary disease.
See page 576
Because comorbid conditions are important, how should
heir effect on outcome be gauged? One very easy way to
easure the burden of comorbid conditions is simply to
ount them—how many problems are on the problem list?
ow many prescription medications does the patient take
very day? A simple count of conditions or of pills would
robably correlate with prognosis, quality of life, and cost. A
imple count of conditions, however, implicitly assumes that
utcome is equally affected by cancer as by hay fever, which
eems implausible. A better method would be to construct
n index that weighs comorbid conditions according to their
mpact on outcome so that cancer counts more heavily than
ay fever. A properly weighted index would allow the effects
f comorbid disease on outcome to be measured precisely.
The concept of a weighted score to gauge the burden of
omorbid disease was applied to the prediction of mortality
n a pioneering study by Charlson et al. (1). They empiri-
ally derived an index that predicted one-year mortality by
tudying 559 patients admitted to the general medical
ervice of Cornell Hospital. They then tested the predictive
ower of their index in an independent cohort of 685
atients. The Charlson index assigns points to various
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Health Research and Policy and the Department of
edicine (Cardiovascular Medicine), Stanford University School of Medicine,tanford, California.onditions, ranging from a weight of 1 for connective tissue
isease to weights of 6 for metastatic solid tumor and for
cquired immune deficiency syndrome; the sum of these
oints forms a global index of comorbidity. The Charlson
ndex has been validated as a predictor of mortality in many
ettings since its original description in 1987 (2,3).
Despite the substantial track record of the Charlson
ndex, there are both conceptual and practical limitations
hen applying it to patients with coronary artery disease
CAD). The Charlson index counts myocardial infarction
nd congestive heart failure as comorbid conditions. In a
ohort of patients with coronary disease, myocardial infarc-
ion and heart failure are not really “comorbid” diseases but
re actually complications of the underlying ischemic heart
isease. Conceptually, these two conditions belong in a
oronary disease severity index, not in a comorbidity index.
t a practical level, the Charlson index was derived in a
ohort of general medical patients, and the list of comorbid
onditions and their weights may not be optimal for
redicting the outcome of patients with CAD. The con-
eptual and practical limitations of the Charlson index
uggest that a measure focused on patients with coronary
isease might be worthwhile.
AD-SPECIFIC INDEX
he study of Sachdev et al. (4) in this issue of the Journal
odified the original Charlson index in two ways: 1)
emoving the coronary disease complications of myocardial
nfarction and heart failure; and 2) reweighing the remain-
ng components of the index based on outcomes among
,471 patients with documented CAD. The weights in their
ew CAD-specific index were derived from a multivariable
ox proportional hazards survival model analysis of 633
eaths observed over a mean follow-up of 13.6 years. The
ew CAD-specific index drops eight comorbid conditions
rom the original Charlson index, adds two conditions
current smoking, hypertension), and increases the weight
iven to four conditions (diabetes, chronic pulmonary dis-
ase, peripheral vascular disease, and renal disease).
Although confirmatory studies are needed to judge its
alue, the new CAD-specific index has considerable face
alidity. The database from which this index was derived
as large, follow-up was lengthy and meticulous, and the
umber of deaths permitted analysis of the effect of multiple
actors on mortality. The comorbid conditions in the index
nclude most of the leading causes of death besides coronary
isease: cancer, chronic respiratory disease, cerebrovascular
isease, diabetes, dementia, and renal disease. Conditions
ncluded in the index are also recognized to increase the
rocedural risk of bypass surgery (5) and percutaneous
oronary intervention (6). The CAD-specific index is likely
o be a very useful measure in studies of mortality among
atients with coronary disease.
The strength of the new CAD-specific index is that it
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Editorial Comment February 18, 2004:583–4as derived empirically from a large cohort of patients
ndergoing coronary angiography. This very strength, how-
ver, implies several important limitations. Comorbid con-
itions that are uncommon among patients undergoing
oronary angiography are not included in the CAD-specific
ndex. A relatively rare disease that carries a very poor
rognosis (e.g., primary biliary cirrhosis, multiple sclerosis)
s unlikely to have a sufficiently strong prognostic “signal” to
each statistical significance in an empirical study of patients
ith coronary disease. Most of the conditions that Sachdev
t al. dropped from the comorbidity index were present in
2% of their patients. Furthermore, patients with advanced
isease in other organ systems who were not candidates for
ggressive treatment were probably not referred to coronary
ngiography. Thus, the CAD-specific index includes only
he most common comorbid conditions that affect subse-
uent mortality.
The CAD-specific index was developed to predict mor-
ality and therefore may not correlate as well with other
utcomes. Osteoarthritis, for example, impairs functional
apacity and increases medical costs. Osteoarthritis is a very
ommon comorbid condition, yet it does not appear in the
AD-specific index because it has little, if any, effect on the
isk of death. Although a comorbidity index may perform
easonably well in predicting outcomes other than death, its
ower to do so will likely be much less than in the predictor
f mortality. The new CAD-specific comorbidity index is aelcome development and highlights the importance of
ther diseases upon outcome in patients with coronary
therosclerosis.
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